The global sclerotherapy market is anticipated to grow at a higher CAGR in the forthcoming period. The primary objective of sclerotherapy is to trigger endothelial and vein wall injury in controlled environment. The resultant is elimination of abnormal vessels that transport retrograde flow without disturbing surrounding vessels that carry normal flow. In such cases, scelosant effect results in a fibrous cord that gets absorbed over time. Therefore, sclerotherapy is used in treatment of all types and dimensions of varicosities.
The therapy is considered as a standard treatment for reticular veins, leg telangiectasias and venulectasias. Sclerotherapy has been standardly used for major varicosities coupled with direct injection into saphenous vein at the saphenofemoral intersection. Therefore, on a commercial level, sclerotherapy is used extensively in treatment of valvular inadequacy of varicose veins.
Driving factors responsible for the growth of sclerotherapy market includes rising incidences of varicose veins and vein surgeries. Other factors such as rise in medical infrastructure, availability of large consumer pool in developed and emerging economies, sedentary lifestyle, rising prevalence of leg casualties stimulate the growth of the industry.
Segmentation based on type, the sclerotherapy market includes detergents, chemical irritants and osmotic agents. Segmentation based on application, the sclerotherapy industry includes hospitals & clinics. Geographically, sclerotherapy market spans North America, South America, Europe, Asia-Pacific, Middle-East and Africa. APAC and MEA market is anticipated to grow at a positive CAGR in the forthcoming period due to rising incidences of varicose veins. Also, growing need for sclerotherapy diagnosis is likely to contribute to these market. Europe and North America market is anticipated to grow at a higher CAGR in the forthcoming period owing to rising incidences of leg injuries, varicose veins and reticular veins.
The key players in the sclerotherapy industry include Kreussler, BTG, LGM Pharma, Changan Tianyu Group, Bioniche Pharma Group Ltd, Omega Pharmaceuticals, Angiodynamics, ENDO-FLEX and MTW ENDOSKOPIE.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Sclerotherapy in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Sclerotherapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• LGM Pharma
• Changan Tianyu group
• Bioniche Pharma Group Ltd
• Omega Pharmaceuticals
• MTW ENDOSKOPIE
• Cook Medical
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Osmotic Agents
• Chemical Irritants
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Research Support Specialist, USA